Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McGill University
$105,000.00
Role of the E2F transcription factors in TGFbeta-mediated tumor suppression
EF 2008-09
Résumé
In humans the process of tumor formation is linked to a series of well-defined events that occur in virtually all human cancers, including the ability of cells to attain immortalization and to evade apoptosis. Transforming growth factor-beta(TGFb) exerts its tumor suppressive effects by inhibiting cell growth, inducing apoptosis and preventing immortalization through inhibition of telomerase activity. While expression of hTERT, the protein component of telomerase, is increased in most cancer cells, we have shown that TGFb represses hTERT expression in both normal and cancer cells. TGFb inhibition of hTERT requires the synthesis of an intermediate molecule that we identified as the transcription factor E2F1. Using the E2F1 knockout mouse model, we found that the loss of E2F1 reverses the TGFb inhibitory effect on telomerase activity. The E2F family of transcription factors play a central role in regulating cell-cycle progression. Deregulation of these factors is a common event in most human cancers. Interestingly, E2F1 has been shown to have the ability to induce both cell cycle progression and apoptosis, though the mechanisms of E2F-mediated apoptosis have not been fully elucidated. As TGFb itself is a potent pro-apoptotic factor, we then investigated the potential implication of the E2F transcription factors in TGFb-mediated apoptosis and found that numerous proapoptotic genes known to be induced by E2F1 are also regulated by TGFb. Our hypothesis is that E2F1 is a critical regulator of TGFb tumor suppressive effects, which exerts its effects by both mediating TGFb-induced inhibition of telomerase and induction of apoptosis. This project aims to characterize the intracellular mechanisms by which TGFb regulates E2F1 expression, the intracellular partners, and downstream E2F1 target genes that mediate TGFb tumor suppressive effects. These studies may prove useful to develop novel prognosis markers for human cancer and open new avenues for future anti-cancer therapies.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
184685
Name
Korah Juliana K
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Role of the E2F transcription factors in TGFbeta-mediated tumor suppression
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Apoptosis; Cancer; E2f; Tgf-Beta; Tumor Suppression
Abstract
In humans the process of tumor formation is linked to a series of well-defined events that occur in virtually all human cancers, including the ability of cells to attain immortalization and to evade apoptosis. Transforming growth factor-beta(TGFb) exerts its tumor suppressive effects by inhibiting cell growth, inducing apoptosis and preventing immortalization through inhibition of telomerase activity. While expression of hTERT, the protein component of telomerase, is increased in most cancer cells, we have shown that TGFb represses hTERT expression in both normal and cancer cells. TGFb inhibition of hTERT requires the synthesis of an intermediate molecule that we identified as the transcription factor E2F1. Using the E2F1 knockout mouse model, we found that the loss of E2F1 reverses the TGFb inhibitory effect on telomerase activity. The E2F family of transcription factors play a central role in regulating cell-cycle progression. Deregulation of these factors is a common event in most human cancers. Interestingly, E2F1 has been shown to have the ability to induce both cell cycle progression and apoptosis, though the mechanisms of E2F-mediated apoptosis have not been fully elucidated. As TGFb itself is a potent pro-apoptotic factor, we then investigated the potential implication of the E2F transcription factors in TGFb-mediated apoptosis and found that numerous proapoptotic genes known to be induced by E2F1 are also regulated by TGFb. Our hypothesis is that E2F1 is a critical regulator of TGFb tumor suppressive effects, which exerts its effects by both mediating TGFb-induced inhibition of telomerase and induction of apoptosis. This project aims to characterize the intracellular mechanisms by which TGFb regulates E2F1 expression, the intracellular partners, and downstream E2F1 target genes that mediate TGFb tumor suppressive effects. These studies may prove useful to develop novel prognosis markers for human cancer and open new avenues for future anti-cancer therapies.
Competitiondate
200810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Korah, Juliana K
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~